Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 ConferencesGlobeNewsWire · Oct 1, 2026
CIRM backs Fate’s FT819 lupus trialDefense World · Sep 29, 2026
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LNGlobeNewsWire · Sep 25, 2026
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026GlobeNewsWire · Sep 16, 2026
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 MeetingGlobeNewsWire · Sep 9, 2026Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.25 | -$0.25 | Beat |
| May 13, 2026 | -$0.29 | -$0.26 | Beat |
| Feb 26, 2026 | -$0.27 | -$0.27 | Beat |
| Nov 13, 2025 | -$0.29 | -$0.27 | Beat |
| Aug 12, 2025 | -$0.35 | -$0.29 | Beat |
| May 13, 2025 | -$0.39 | -$0.32 | Beat |